Evidence map›Paper›PMID 17599049›Full record

ArticleOncogene2007

Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen.

H Hao, M d'Alincourt-Salazar, K M M Kelley, A Shatnawi, S Mukherjee, Y M Shah, M Ratnam

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Cure and Long-Term Remission Strategies.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  3. Article
  4. Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

H HaoDepartment of Biochemistry and Cancer Biology, Medical University of Ohio, Toledo, OH 43614, USA.
M d'Alincourt-Salazar
K M M Kelley
A Shatnawi
S Mukherjee
Y M Shah
M Ratnam
University of Toledo · USUniversity of Toledo Medical Center · US

Funding

MECHANISMS CONTROLLING EXPRESSION OF NEW TUMOR TARGETSR01CA080183 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI RATNAM, MANOHAR · 1999 to 2009
$1.9M
Regulation of a Tumor Target Through Steroid ReceptorsR01CA103964 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI RATNAM, MANOHAR · 2004 to 2008
$1.3M
NCI NIH HHS CA 103964NCI NIH HHS CA 80183NCI NIH HHS R01 CA080183NCI NIH HHS R01 CA103964
6 · The paper itself

Abstract

Estradiol (E2) acts through the estrogen receptor (ER) to downregulate many genes, and tamoxifen (Tam) largely reverses this repression but the underlying mechanisms are unclear. Repression of the folate receptor (FR)-alpha P4 core promoter by ER is enhanced by E2 and reversed by Tam. This effect was unaffected by inhibition of new protein synthesis and required the E/F and the DNA-binding domains of ER without direct binding of ER to DNA. The repression by E2/ER was not specific for either Sp1 or TATA elements but was loosely selective for the initiator and flanking sequence. Insertion of a response element or a relatively strong Sp1 cluster to recruit ER upstream of the core promoters caused a switch to activation by E2/ER that was inhibited by Tam. In nuclear extracts, association of ER with a biotinylated core promoter fragment was promoted by E2 but Tam blocked this effect. Repression/de-repression of the P4 promoter and endogenous FR-alpha expression by E2/Tam required SMRT and/or NCoR. ER associated with the chromosomal P4 promoter and SMRT and NCoR associated with it in an ER-dependent manner; these associations were favored by E2 but disrupted by Tam, in the short term, without changes in ER expression. TAFII30 was required for optimal P4 promoter activity and for the repressive association of ER. E2 may thus maintain a low transcriptional status of genes by favoring direct TAFII30-dependent association of ER with the core promoter in a co-repressor complex containing SMRT and/or NCoR; this repression is overridden in target genes containing an upstream element that strongly recruits ER. In addition to suppressing the activation of classical E2 target genes, Tam may upregulate genes by passively dissociating the ER co-repressor complex.

Indexed as

Promoter Regions, GeneticCarrier ProteinsCycloheximideDNA-Binding ProteinsEstradiolFemaleFolate Receptors, GPI-AnchoredGene Expression RegulationHeLa CellsHumansNuclear Receptor Co-Repressor 2Protein Structure, TertiaryReceptors, Cell SurfaceReceptors, EstrogenRepressor ProteinsTamoxifenCarrier ProteinsCycloheximideDNA-Binding ProteinsEstradiolFolate Receptors, GPI-AnchoredNCOR2 protein, humanNuclear Receptor Co-Repressor 2Receptors, Cell SurfaceReceptors, EstrogenRepressor ProteinsTAF10 protein, humanTamoxifenTATA-Binding Protein Associated FactorsTranscription Factor TFIID

Identifiers

PMID17599049
OpenAlexW2043142184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.